Pakistan is facing a shortage of several established influenza vaccine brands, while drug inspectors in Lahore have seized a large quantity of suspected counterfeit flu vaccines and arrested two people, according to Punjab drug control officials.
The developments have raised concerns about vaccine availability and the risks posed by falsified medical products as demand for seasonal influenza protection increases ahead of winter.
The seizure comes amid reported supply disruptions involving multinational manufacturers Abbott and Sanofi, as well as limited supplies from Chinese producers. However, the extent of the shortage remains disputed.
Federal Health Minister Mustafa Kamal said on October 23 that other influenza vaccine brands remained available, despite the absence of certain multinational products.
Lahore Raid Targets Suspected Counterfeit Influenza Vaccines
An official from the Office of the Chief Drug Controller Punjab said drug inspectors seized a large stock of suspected counterfeit vaccines during a raid in Lahore and arrested two individuals.
The product reportedly appeared to be a falsified version of Influvac. Authorities have not publicly disclosed the quantity seized or the identities of the suspects in the information available for this report.
The seized stock must be assessed by the relevant authorities to establish its authenticity and origin. The allegations remain under investigation, and the arrested individuals should be presumed innocent unless proven guilty.
Separately, the Drug Regulatory Authority of Pakistan (DRAP) issued a safety alert on October 27 concerning a falsified batch of Vaxigrip Tetra influenza vaccine.
According to DRAP’s official alert, batch number Y4B34 was purportedly manufactured by Sanofi Winthrop Industrie in France but had never been imported or distributed in Pakistan.
DRAP warned that the falsified product could pose serious safety and quality risks. It directed regulatory field teams and provincial drug control departments to conduct surveillance and confiscate the affected product.
The Vaxigrip Tetra alert concerns a specific batch and should not be confused with the separate Influvac stock seized in Lahore.
Major Vaccine Brands Face Supply Disruptions
An official from the Punjab drug control department said influenza vaccines from major suppliers were unavailable in the market at the time of the reported shortage.
According to the official, Abbott might not supply its influenza vaccine to Pakistan this year, while Sanofi could deliver only limited quantities towards the end of November or in December.
The official also said supplies from Chinese manufacturers Sinovac and Shenzhen Innovax had been exhausted after limited quantities entered the market.
However, the federal health minister has offered a different assessment, saying vaccines from other manufacturers remained available and that the absence of particular multinational brands did not constitute a nationwide shortage.
Reporting by The News International also linked the unavailability of multinational vaccines to pending government decisions on revised retail prices.
The differing accounts suggest that availability may vary by brand and location. Consumers should therefore check with licensed pharmacies and healthcare providers rather than assume that all influenza vaccines are unavailable.
Pricing Dispute Adds to Supply Concerns
The supply disruption has coincided with an unresolved process involving proposed price revisions for influenza vaccines.
In an October 24 report, Geo News said Climate Change Minister Dr. Musadik Malik had asked DRAP to reassess certain medicine pricing proposals, including those relating to influenza vaccines, after a review identified issues requiring further examination.
The reports indicate that the availability of some multinational vaccines has been affected by the pricing process. However, the exact effect on national vaccine supplies cannot be established from the available information alone.
DRAP Advises Consumers to Use Authorised Supply Channels
DRAP advises consumers to obtain therapeutic products only from licensed pharmacies and other authorised retail outlets. Its alert specifically instructs consumers not to use Vaxigrip Tetra bearing batch number Y4B34.
Anyone who has obtained this specific batch should contact their healthcare provider and follow DRAP’s instructions. Suspected adverse reactions or product-quality problems should be reported to the regulator.
Consumers should not rely on packaging or a manufacturer’s seal alone to establish that a vaccine is genuine. Pharmacists and healthcare professionals should verify products through authorised suppliers and check the relevant batch information.
Vaccines also require appropriate temperature-controlled storage and transportation. If a product’s authenticity or storage conditions are uncertain, consumers should consult a qualified pharmacist or healthcare professional before use.
Further notices can be checked through DRAP’s official alerts and updates.
Why Reliable Flu Vaccine Supplies Matter
Seasonal influenza can cause serious complications, particularly among older adults, young children, pregnant women and people with certain chronic conditions. Access to authorised vaccines is therefore an important public health consideration.
The current situation highlights the importance of reliable import arrangements, transparent medicine pricing, effective supply-chain monitoring and prompt action against falsified products.
For consumers, the immediate priority is to obtain vaccination through authorised healthcare channels and seek professional advice about suitable products. For regulators, the Lahore investigation and DRAP’s separate vaccine alert underscore the need to identify suspect stock, verify its origin and communicate precise product information to the public.
The extent of the reported shortage and the authenticity of the stock seized in Lahore will become clearer as authorities provide further information.
